<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tularemia: Clinical manifestations, diagnosis, treatment, and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tularemia: Clinical manifestations, diagnosis, treatment, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tularemia: Clinical manifestations, diagnosis, treatment, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Penn, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tularemia is a zoonotic infection caused by <em>Francisella tularensis</em>, an aerobic and fastidious gram-negative bacterium. Human infection occurs following contact with infected animals or invertebrate vectors. Synonyms include Francis disease, deer-fly fever, rabbit fever, market men disease, water-rat trappers disease, wild hare disease (yato-byo), and Ohara disease [<a href="#rid1">1</a>]. The clinical manifestations of <em>Francisella</em> infection may range from asymptomatic illness to septic shock and death, in part depending on the virulence of the infecting strain, portal of entry, inoculum, and the immune status of the host [<a href="#rid1">1</a>].</p><p>The clinical manifestations, diagnosis, treatment, and prevention of tularemia will be reviewed here. The microbiology, pathogenesis, and epidemiology of infection due to <em>F. tularensis</em> are discussed separately. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1645550846"><span class="h2">Initial nonspecific symptoms</span><span class="headingEndMark"> — </span>Tularemia usually has an abrupt or rapid onset of nonspecific systemic symptoms, including fever, chills, anorexia, and malaise, which occur approximately three to five days (range 1 to 21 days) following exposure. Classically, the fever may abate after a few days but then quickly return. Other nonspecific symptoms include headache, fatigue, soreness in the chest or muscles, abdominal pain, emesis, or diarrhea. In some patients, these systemic symptoms may have waned by the time of evaluation. </p><p>When patients do come to medical attention, they usually have specific clinical manifestations associated with one of the six major clinical forms of tularemia, depending on the portal of entry [<a href="#rid2">2</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Ulceroglandular tularemia</p><p class="bulletIndent1"><span class="glyph">●</span>Glandular tularemia</p><p class="bulletIndent1"><span class="glyph">●</span>Oculoglandular tularemia</p><p class="bulletIndent1"><span class="glyph">●</span>Pharyngeal (oropharyngeal) tularemia</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonic tularemia</p><p class="bulletIndent1"><span class="glyph">●</span>Typhoidal tularemia</p><p></p><p>These syndromes are discussed separately in detail below, although overlapping manifestations may be present.</p><p>Some features may depend on the infecting subtype. Pulse-temperature dissociation (eg, relative bradycardia in the setting of a fever) was reported in only 5 percent of patients in a series from Sweden, where <em>F. tularensis</em> subspecies <em>holarctica</em> predominates, but was reported in 42 percent of patients in a series from the United States, where <em>F. tularensis</em> subspecies <em>tularensis</em> predominates [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H17567759"><span class="h2">Clinical syndromes</span></p><p class="headingAnchor" id="H3"><span class="h3">Ulceroglandular disease</span><span class="headingEndMark"> — </span>Ulceroglandular disease, characterized by a skin lesion and associated adenopathy, is the most common and most easily recognizable form of tularemia [<a href="#rid1">1,2</a>]. As an example, in a review of 190 tularemia cases in Missouri between 2000 and 2007, ulceroglandular tularemia was the most common clinical form overall and among adults; among children, it was the second most common form (glandular disease was the most common among children) [<a href="#rid4">4</a>]. Ulceroglandular disease was also among the most common forms of tularemia during 2015 in Colorado, Nebraska, South Dakota, and Wyoming: states with significantly increased numbers of cases during that time [<a href="#rid5">5</a>]. Among 177 tularemia patients identified in France between 2008 and 2017, ulceroglandular disease was the most common presentation; all were infected with <em>F. tularensis</em> subspecies <em>holarctica</em> [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis"</a>.) </p><p>Patients with ulceroglandular disease usually report recent animal contact or exposure to potential insect vectors (particularly ticks). They typically present with fever and a single erythematous papulo-ulcerative lesion with a central eschar at the site of inoculation (eg, the site of a tick bite) (<a class="graphic graphic_picture graphicRef51005" href="/d/graphic/51005.html" rel="external">picture 1</a>). Ulcers on the hands and arms are more common following animal exposures; ulcers on the head or neck, trunk, perineum, and legs are more common following tick exposures. Occasionally, more than one skin lesion may be present [<a href="#rid2">2</a>]. </p><p>Affected patients also have tender regional lymphadenopathy, which can occur before, at the same time, or shortly after the appearance of the skin lesion. Adenopathy involving cervical or occipital nodes is more common in children than adults, and the associated ulcers may be hidden in the scalp. The overlying skin of the node can be erythematous, as observed in 19 percent of cases in a series of 215 Swedish patients with infection due to the less virulent <em>F. tularensis</em> subspecies <em>holarctica </em>[<a href="#rid3">3</a>]. A "sporotrichoid" presentation, or subcutaneous nodules along the draining lymphatics, has also been described in some patients with tularemia [<a href="#rid7">7</a>]. However, frank lymphangitis is not usually seen; its presence should suggest the uncommon complication of bacterial superinfection of the skin ulcer. </p><p>Suppuration of affected lymph nodes is a relatively common complication and may occur despite antibiotic therapy. In a review of tularemia cases in Missouri, 15 of 81 patients (19 percent) with lymphadenopathy required incision and drainage of suppurative nodes [<a href="#rid8">8</a>]. Recurrent lymph node suppuration despite treatment has been described in a patient with tularemia who had been treated with an anti-tumor necrosis factor (TNF) agent and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid9">9</a>]. Suppurated, fluctuant nodes warrant surgical or needle drainage. (See <a class="local">'Adjunctive management'</a> below.) </p><p>Patients seeking medical attention relatively late in the course of disease may have adenopathy with little or no fever and only evidence of a healed skin lesion.</p><p class="headingAnchor" id="H4"><span class="h3">Glandular disease</span><span class="headingEndMark"> — </span>Glandular tularemia refers to tender regional lymphadenopathy involving single or multiple nodes, in the absence of an identifiable skin lesion. It is a relatively common presentation of tularemia. Among 190 cases of tularemia in Missouri between 2000 and 2007, glandular disease was the most common presentation among children (44 percent of cases), and it was the second most common presentation overall (28 percent of cases); it was the third most common presentation in adults (16 percent of cases) [<a href="#rid4">4</a>]. Among 177 tularemia patients identified in France between 2008 and 2017, glandular disease was the second most common presentation [<a href="#rid6">6</a>].</p><p>Glandular disease is transmitted via the same mechanism as ulceroglandular disease, and the clinical features of the associated adenopathy are the same, but in glandular disease, there is no evident lesion at the site of inoculation. Suppurative lymph nodes can also occur with glandular disease. (See <a class="local">'Ulceroglandular disease'</a> above.)</p><p class="headingAnchor" id="H280874049"><span class="h3">Oculoglandular disease</span><span class="headingEndMark"> — </span>Oculoglandular tularemia refers to infection involving the eye and accounts for a small percentage of tularemia cases. </p><p>It occurs when <em>F. tularensis</em> gains access to the conjunctiva, either via splashing infected material into the eye, rubbing the eyes with contaminated fingers, or by infected aerosols. Eye symptoms are usually unilateral and include pain, photophobia, and increased tearing. Eye examination demonstrates conjunctival erythema with edema and vascular engorgement. Some patients may have conjunctival purulence, small conjunctival ulcers or nodules, and periorbital erythema and/or edema [<a href="#rid10">10</a>]. Tender regional adenopathy may be present in the preauricular, postauricular, cervical, and submandibular regions. Parinaud's oculoglandular syndrome specifically refers to conjunctivitis in one eye and swollen lymph nodes in front of the ear on the same side; <em>F. tularensis </em>is one cause of this syndrome. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Complications include corneal ulceration and dacryocystitis. Tularemia also has been associated with other less common ocular manifestations, including a case of unilateral uveitis [<a href="#rid11">11,12</a>].</p><p>Suppurative lymph nodes can also occur with oculoglandular disease. (See <a class="local">'Ulceroglandular disease'</a> above.)</p><p class="headingAnchor" id="H280874057"><span class="h3">Pharyngeal (oropharyngeal) disease</span><span class="headingEndMark"> — </span>Pharyngeal tularemia involves the mouth and throat and accounts for a small percentage of cases in the United States. However, pharyngeal disease accounts for a larger percentage of cases in other parts of the world, particularly in outbreaks in the setting of war or natural disaster [<a href="#rid13">13</a>]. </p><p>It results from an oropharyngeal portal of infection, usually ingestion of contaminated food or water. Transmission can also occur from oral exposure to contaminated droplets or by hand-to-mouth exposure (eg, in the setting of finger contamination from crushing ticks or handling contaminated animals). </p><p>The major symptoms are fever, severe sore throat, and swelling in the neck [<a href="#rid14">14</a>]. Examination demonstrates an exudative pharyngitis and tonsillitis, cervical lymph node enlargement, and usually pharyngeal or tonsillar ulcers. Preparotid and retropharyngeal lymph nodes also may be enlarged and tender. In addition, a pharyngeal membrane mimicking diphtheria can occur [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Pneumonic disease</span><span class="headingEndMark"> — </span>Pneumonic tularemia refers to a clinical presentation dominated by pulmonary involvement. Pneumonic disease is more common in adults but can affect any age group and has occurred with increasing frequency. Among 190 cases in Missouri between 2000 and 2007, pneumonic disease accounted for 39 percent of adult cases and 24 percent of tularemia cases overall [<a href="#rid4">4</a>]. Pneumonic and ulceroglandular tularemia were equally common in Colorado, Nebraska, South Dakota, and Wyoming during 2015, a year when there was a significant increase in the number of tularemia cases in these states [<a href="#rid5">5</a>]. Pneumonic disease caused by <em>F. tularensis</em> subspecies <em>tularensis</em> (prevalent in North America) is generally more severe than that caused by subspecies <em>holarctica</em> (prevalent in other parts of the world) [<a href="#rid16">16,17</a>]; however, subspecies <em>holarctica</em> may also cause severe pneumonia, particularly in immunocompromised patients [<a href="#rid18">18</a>]. </p><p>Pneumonic disease can be categorized as primary or secondary, based on the route of transmission. </p><p class="bulletIndent1"><span class="glyph">●</span>Primary pneumonic disease results from direct inhalation of the organism into the lungs. Occupations at particular risk for primary disease include farmers, sheep shearers, landscapers, and laboratory workers. </p><p></p><p class="bulletIndent1">Following the initial nonspecific symptoms (eg, fever, headache, malaise, myalgias, nausea, and anorexia), fevers, chest pain, and cough with scant sputum production become more pronounced [<a href="#rid19">19,20</a>]. Patients sometimes complain of substernal or pleuritic chest pain. Findings on chest examination include rales, signs of consolidation, and a friction rub or evidence of pleural fluid. </p><p></p><p class="bulletIndent1">Early after inhalational exposure, the chest radiograph may be normal, but abnormalities usually develop as respiratory findings become more prominent [<a href="#rid19">19</a>]. Common radiographic changes include peribronchial infiltrates, lobar consolidation, pleural effusion, and hilar adenopathy. Rounded infiltrates and cavitation from pneumonic tularemia are uncommon, although the presence of nodular infiltrates with a pleural effusion should raise concern for tularemic pneumonia or pneumonic plague. (See  <a class="medical medical_review" href="/d/html/3131.html" rel="external">"Clinical manifestations, diagnosis, and treatment of plague (<i>Yersinia pestis</i> infection)", section on 'Clinical manifestations'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary pneumonic disease results from hematogenous spread to the lung. Secondary pneumonic disease can complicate any of the major forms of tularemia but is most common with the typhoidal and ulceroglandular forms [<a href="#rid2">2,21</a>]. </p><p></p><p class="bulletIndent1">The clinical presentation of secondary pneumonic tularemia is varied. Secondary pneumonia can present with bilateral disease, involvement of the lower lobes, and/or with miliary disease. There can be pulmonary infiltrates, pleural effusion, or both. In one series, some patients with secondary lung involvement had abnormal chest radiographs but no clinical evidence of pneumonia [<a href="#rid2">2</a>]. Pulmonary nodules, pleural effusion, and mediastinal adenopathy have been described in a patient with typhoidal tularemia who had been treated with the anti-tumor necrosis factor agent <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid22">22</a>]. </p><p></p><p>Pleural effusions in pneumonic tularemia are exudative with a lymphocytic predominance and may have an elevated adenosine deaminase level [<a href="#rid23">23</a>]. Pleural or lung biopsies can demonstrate granuloma formation and therefore be confused with pulmonary tuberculosis [<a href="#rid1">1,23</a>]. Empyema requiring decortication has been reported [<a href="#rid8">8</a>]. </p><p>Respiratory failure requiring mechanical ventilation and the adult respiratory distress syndrome can result from either primary or secondary pneumonic tularemia. In one series of 128 patients with tularemia, those with pneumonic disease were more likely to have underlying typhoidal illness, to recall no potential exposure, to require hospitalization, to have a longer hospital stay, to have positive cultures, and to have a higher mortality rate compared with those without pulmonary involvement [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3860059183"><span class="h3">Typhoidal disease</span><span class="headingEndMark"> — </span>Typhoidal tularemia is a systemic febrile illness without prominent regional adenopathy or other localizing signs that does not fit another major form of the disease. Typhoidal disease is a common presentation in certain locations. As an example, in the United States, it was the most common tularemia presentation among cases reported in Arkansas from 2009 through 2013 and was particularly frequent among older patients [<a href="#rid24">24</a>], and it was among the most common forms during 2015 in Colorado, Nebraska, South Dakota, and Wyoming [<a href="#rid5">5</a>].</p><p>Typhoidal disease may result from any portal of entry, but the source is usually inapparent at the time of presentation. Affected patients often have chronic underlying conditions.</p><p>The clinical presentation ranges from acute sepsis to a chronic febrile illness. Major symptoms include fever, chills, anorexia, headache, myalgias, sore throat, cough, abdominal pain, and diarrhea. Prominent physical findings may include evidence of intravascular volume depletion, mild pharyngitis, and diffuse abdominal tenderness. </p><p>Occasionally, localizing findings can be present. A clinical presentation with predominant abdominal symptoms has been referred to as "abdominal tularemia," potentially from ingestion of the pathogen; mesenteric adenopathy can be present. Enlargement of the liver and spleen is more likely to be detectable with a longer duration of illness. Pulmonary involvement secondary to hematogenous spread is seen in up to 45 percent of cases [<a href="#rid1">1</a>]. (See <a class="local">'Pneumonic disease'</a> above.)</p><p>Potential laboratory findings in severe typhoidal tularemia include elevated creatine phosphokinase (CPK), myoglobinuria, hyponatremia, and renal failure.</p><p class="headingAnchor" id="H238061194"><span class="h2">Presentation in immunocompromised patients</span><span class="headingEndMark"> — </span>Immunocompromised patients with tularemia usually have fever with or without any of the nonspecific symptoms described above (see <a class="local">'Clinical syndromes'</a> above). They may be more likely to present with pneumonic or typhoidal illness. </p><p>A review of 17 immunocompromised individuals with tularemia reported fever in 94 percent, sweats or fatigue in 36 percent, respiratory symptoms in 41 percent, and abdominal symptoms in 24 percent [<a href="#rid25">25</a>]. Eight patients (48 percent) presented with pneumonic tularemia, five (29 percent) had typhoidal tularemia, and only four (24 percent) had ulceroglandular or glandular disease.</p><p class="headingAnchor" id="H3220848484"><span class="h2">Other features</span></p><p class="headingAnchor" id="H280874625"><span class="h3">Secondary skin manifestations</span><span class="headingEndMark"> — </span>Secondary skin changes are common in all forms of tularemia, reported in up to 50 percent in some series, and are often misdiagnosed or overlooked [<a href="#rid3">3,26-28</a>]. These secondary eruptions are usually maculopapular, vesiculopapular, erythema multiforme, erythema nodosum, or urticarial; some have been mistaken for varicella or drug eruptions [<a href="#rid27">27</a>]. Sweet syndrome also has been reported to occur with tularemia [<a href="#rid28">28</a>]. More than one type of eruption can occur in the same patient [<a href="#rid29">29</a>]. </p><p>The character of the skin eruption may vary with the underlying type of tularemia. Patients with typhoidal tularemia can have erythema multiforme or erythema nodosum, whereas patients with pneumonic tularemia are more likely to have erythema nodosum. In Turkey, where oropharyngeal disease is common, erythema multiforme has been reported most often with oropharyngeal or glandular tularemia [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2174908894"><span class="h3">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory tests are nonspecific. The white blood cell count may be low, normal, or elevated. Other nonspecific findings may include low platelet count, low serum sodium, abnormal liver enzymes, evidence of rhabdomyolysis or myoglobinuria, and pyuria.</p><p class="headingAnchor" id="H280874633"><span class="h3">Complications</span><span class="headingEndMark"> — </span>If untreated, tularemia can cause prolonged fever, weight loss, adenopathy, and debility that can last for weeks or months [<a href="#rid15">15</a>]. Even with appropriate treatment, some patients will have a lengthy recovery following tularemia. </p><p>Patients with prolonged tularemia often complain of fatigue and lassitude, and may have anorexia, weakness, and weight loss. Neuropsychiatric complaints include headache, difficulty concentrating, and disturbed sleep [<a href="#rid31">31</a>]. Many of these patients have had suppurative lymph nodes, a common complication when lymph nodes are involved (see <a class="local">'Ulceroglandular disease'</a> above). Risk factors for a poor outcome include older age, serious underlying disease, a delay in correct diagnosis, prolonged symptoms prior to treatment, pneumonic or typhoidal disease, renal failure, and inadequate antibiotic treatment [<a href="#rid21">21,32</a>].</p><p>Other complications include sepsis, renal failure, rhabdomyolysis, and hepatitis [<a href="#rid2">2,32</a>]. Rarely, <em>F. tularensis</em> infection may cause otitis media and mastoiditis, endocarditis, pericarditis, myocarditis, meningitis, osteomyelitis, peritonitis, granulomatous hepatitis, splenic hematoma, spontaneous splenic rupture, aortitis, or prosthetic joint infection [<a href="#rid1">1,6,33-38</a>]. All four patients identified in one literature review of <em>F. tularensis</em> endocarditis initially presented with typhoidal disease [<a href="#rid35">35</a>]. <em>F. tularensis</em> subspecies <em>holarctica</em> infection of a bioprosthetic valve occurred in a patient presenting with prolonged fever and a resolving skin lesion [<a href="#rid39">39,40</a>]. Meningitis, reported with ulceroglandular and typhoidal disease, can develop 3 to 30 days after the onset of illness and cause a cerebrospinal fluid mononuclear cell pleocytosis with low glucose and high protein [<a href="#rid41">41-43</a>]. Meningitis developed in a patient with fever and rash after he ran his lawn mower over a dead rabbit [<a href="#rid43">43</a>]. Other rare neurological manifestations attributed to tularemia include Guillain-Barré syndrome and isolated cranial nerve abnormalities [<a href="#rid44">44,45</a>].</p><p>One report described a patient whose only manifestation of tularemia was pericarditis; the diagnosis was made serologically [<a href="#rid46">46</a>]. </p><p class="headingAnchor" id="H280874727"><span class="h3">Potential bioterrorism use</span><span class="headingEndMark"> — </span><em>F. tularensis</em> is a category A bioterrorism agent (ie, of highest concern for bioterrorism use), as classified by the United States Centers for Disease Control and Prevention, in part because of its low infectious dose, high associated mortality, and potential for easy dissemination. </p><p>A bioterrorist attack with <em>F. tularensis</em> would most likely employ aerosolization of the organism to do the most harm to the most people [<a href="#rid47">47</a>]. Such an attack would most likely result in an outbreak of inhalational tularemia three to five days later, marked by an acute, undifferentiated febrile illness with predominant manifestations of pneumonia, pleuritis, and hilar lymphadenopathy [<a href="#rid47">47</a>]. Because an airborne organism could still invade through sites other than the lung and could contaminate food and water, other clinical forms of tularemia would also occur, including typhoidal, pharyngeal, and ocular tularemia [<a href="#rid1">1,47</a>]. </p><p>Rapid recognition and reporting of a possible bioterrorist event due to tularemia is thus a difficult clinical challenge. The possibility should be suggested by clustered cases of pneumonic or typhoidal disease, particularly in urban areas in patients without the expected epidemiologic exposures to animals, insects, or environmental activities. </p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2477320528"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>Tularemia should be suspected in patients with a compatible clinical syndrome and epidemiologic risk factors. Because laboratory confirmation may be delayed, the initial diagnosis of tularemia is often made presumptively, when the patient's presentation is both clinically and epidemiologically consistent and there is no more likely cause.</p><p>Specific clinical features that should prompt consideration for tularemia include:</p><p class="bulletIndent1"><span class="glyph">●</span>Regional lymphadenopathy, particularly if associated with an inoculation site</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctivitis accompanied by local lymphadenopathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe pharyngitis that is unresponsive to penicillin and undiagnosed after routine testing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent systemic febrile illness that is undiagnosed after routine testing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Community-acquired pneumonia that is unresponsive to standard antibiotic therapy and undiagnosed after routine testing </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular infiltrates plus a pleural effusion on chest imaging</p><p></p><p>When these clinical features are observed in the setting of a history of animal (particularly wild animal) exposure or insect bites, the possibility of tularemia is greater, and making the presumptive diagnosis is reasonable. In particular, people who are farmers, veterinarians, hunters, national park service employees, landscapers, meat handlers, or laboratory workers are at increased risk for exposure. The patient's location, activities, and travel history also should inform the likelihood of tularemia. It has been reported globally, but is less common in Africa, South America, Australia, and England. In the United States, it is most commonly reported in the south-central states, the Pacific Northwest, and parts of Massachusetts (<a class="graphic graphic_figure graphicRef68457" href="/d/graphic/68457.html" rel="external">figure 1</a>). Clusters of cases, particularly of infections consistent with pneumonic tularemia in the absence of typical exposures, should raise suspicion for the possibility of a bioterrorism event. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis", section on 'Epidemiology'</a>.)</p><p>The diagnosis of tularemia requires a high index of suspicion, as the exposure history or epidemiologic risk may not be evident, and certain signs, such as fever or lesions around an inoculation site, may have abated by the time of presentation. </p><p>Meningitis is a rare complication of tularemia. Patients with suspected tularemia who have progressive headache, signs of meningeal irritation, or altered mental status warrant evaluation for meningitis with lumbar puncture. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Cerebrospinal fluid examination'</a>.) </p><p class="headingAnchor" id="H282087341"><span class="h2">Microbiologic diagnosis</span></p><p class="headingAnchor" id="H1117951283"><span class="h3">Approach</span><span class="headingEndMark"> — </span>When tularemia is clinically suspected, serology for <em>F. tularensis</em> should be submitted at the time of presentation and again at least two to four weeks after presentation. This is because it takes at least two weeks after infection for antibodies to <em>Francisella</em> to be detectable, and diagnostic rises in convalescent antibody titers do not appear until at least two to four weeks after the onset of symptoms. The diagnosis is confirmed with a fourfold or greater change in titer from the initial to convalescent serology. Relevant patient specimens (such as ulcer exudate, blood, specimens from fluctuant or necrotic lymph nodes, sputum, and tissue biopsies) should also be sent for culture with specific instructions to the laboratory that tularemia is suspected; cultures are diagnostic if positive, but do not rule out the possibility of tularemia if negative. Molecular, direct fluorescent antibody, and immunohistochemical tests on such specimens could rapidly identify <em>F. tularensis</em> while awaiting serologic confirmation, but these tests are not widely available for routine use. (See <a class="local">'Serology'</a> below and <a class="local">'Culture'</a> below and <a class="local">'Molecular and other novel testing'</a> below.)</p><p>In the event of a suspected bioterrorist event using <em>F. tularensis</em>, steps to alert the appropriate authorities should be taken. These include immediate activation of local emergency response systems, immediate notification of infection control personnel and health care facility administration, and prompt notification of local and state health departments [<a href="#rid48">48</a>]. </p><p>In the United States, the Federal Bureau of Investigation field office, local police, the Centers for Disease Control and Prevention (CDC), and medical emergency services should be informed in accordance with the local emergency response plan [<a href="#rid48">48</a>]. Specimens can be submitted to a specialized laboratory in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Femergency.cdc.gov%2Flrn%2Findex.asp&amp;token=%2FXpciKoGXD%2FNBcI56myByC78r1g42d9%2BGqNDkCc%2BGMcQajG7Fwi5MjudPS1Y59rK&amp;TOPIC_ID=3141" target="_blank">Laboratory Response Network</a> for direct visualization of the organism and other rapid diagnostic tests. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H4123942667"><span class="h3">Serology</span><span class="headingEndMark"> — </span>The diagnosis of tularemia is usually confirmed serologically by detecting a fourfold or greater change in titers of antibodies to <em>F. tularensis</em> between acute and convalescent serum specimens [<a href="#rid49">49</a>]. Tube agglutination titers of 1:160 or higher or microagglutination titers of 1:128 or higher are considered positive [<a href="#rid49">49</a>]. The results of serologic testing should always be interpreted in the context of the clinical suspicion for tularemia. Serologic studies should be performed only in patients in whom tularemia is a realistic possibility; they should not be used as a screening test among febrile patients.</p><p>A diagnostic increase in antibody titer generally occurs two to four weeks after the onset of symptoms. Antibody titers are not reliably positive until after at least two weeks of infection, so they are rarely helpful in the acute setting. Both IgM and IgG antibodies appear together following the initial infection, and both antibody titers may remain elevated for years after an infection. Thus, a single positive titer is supportive of the diagnosis, but may also result from an old infection [<a href="#rid50">50</a>]. Serologic assays for tularemia can cross-react with heterophile antibodies and antibodies to other gram-negative organisms such as <em>Brucella</em> or <em>Legionella</em>, but cross-reactions are typically positive at a low, non-diagnostic titer [<a href="#rid1">1,51</a>].</p><p>In the United States, serologic studies are typically performed using a tube agglutination or microagglutination assay; commercially available enzyme-linked immunosorbent assays (ELISAs) have been used more commonly in Europe than in the United States. Serologic tests cannot identify the specific infecting <em>F. tularensis</em> subspecies. Investigational methods to improve serodiagnostic testing are being pursued [<a href="#rid52">52,53</a>]. </p><p class="headingAnchor" id="H2411958600"><span class="h3">Culture</span><span class="headingEndMark"> — </span>Gram stain and culture are rarely positive for <em>F. tularensis</em>, but positive cultures can confirm the diagnosis, allow subspecies identification, and permit antibiotic susceptibility testing. Thus, it is appropriate to submit relevant specimens for culture when tularemia is suspected. Depending on the clinical presentation, relevant specimens include blood, lymph node drainage or biopsy specimens, skin lesion drainage or biopsy specimens, pleural fluid, sputum, and pharyngeal or ocular swabs. The laboratory should be notified prior to obtaining specimens for culture to optimize growth conditions as well as to take proper precautions to reduce the risk of infection among laboratory personnel. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis", section on 'Laboratory precautions'</a>.)</p><p>When <em>F. tularensis</em> is seen on Gram stain of clinical specimens, it appears as weakly stained, tiny gram-negative coccobacilli. Routine cultures are frequently negative because the organism is quite fastidious. In addition, most routine solid media do not contain cysteine, which many <em>Francisella</em> strains require for growth. Culture growth is facilitated by use of supportive media. Other details regarding the growth and identification of <em>F. tularensis</em> are found elsewhere. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis", section on 'Laboratory features'</a>.)</p><p class="headingAnchor" id="H1844207043"><span class="h3">Molecular and other novel testing</span><span class="headingEndMark"> — </span>Polymerase chain reaction (PCR) assays can be performed on human specimens for the rapid presumptive diagnosis of tularemia while awaiting serologic confirmation, but these tests are generally not yet available for routine testing in most hospital or clinical labs. Appropriate samples may include ulcer exudates, lymph node aspirates, blood, respiratory secretions, pleural fluid, spinal fluid, or tissue biopsies. <em>Francisella</em> PCR assays offer the potential advantages of a more rapid diagnosis than serologic tests or cultures, a greater sensitivity than smears or cultures, a more limited exposure of laboratory personnel to the potential hazards of processing cultures, and the availability of the basic methodology in many clinical laboratories. PCR may also eventually prove useful for the diagnosis of patients with prolonged illness and in those already given antibiotic treatment. </p><p>Real-time PCR assays have been developed that can distinguish between <em>F. tularensis</em> subspecies <em>tularensis</em> types A1 and A2, as well as among <em>F. tularensis</em> subspecies [<a href="#rid54">54,55</a>]. A sensitive, cartridge-based, automated PCR assay is able to detect <em>F. tularensis</em> bacteremia in a primate model, and a commercially available multiplex PCR system has been used successfully to diagnose tularemia [<a href="#rid56">56,57</a>].</p><p>Other specific techniques for the rapid presumptive diagnosis of tularemia have been developed, including direct fluorescent antibody (DFA) staining of clinical specimens and immunohistochemical staining of tissue [<a href="#rid1">1,49</a>]. However, these methods are not commercially available. In the United States, DFA and PCR assays can be obtained through state public health laboratories and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Femergency.cdc.gov%2Flrn%2Findex.asp&amp;token=%2FXpciKoGXD%2FNBcI56myByC78r1g42d9%2BGqNDkCc%2BGMcQajG7Fwi5MjudPS1Y59rK&amp;TOPIC_ID=3141" target="_blank">Laboratory Response Network</a>.</p><p>Rapid tests to detect multiple potential bioterrorism pathogens simultaneously are being explored, as are genomic, proteomic, metabolomic, and immunologic methods for diagnosis. </p><p class="headingAnchor" id="H2601902282"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of tularemia is broad and depends on the predominant clinical syndrome. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever and lymph node enlargement (ulceroglandular and glandular disease)</strong> – Many other infectious and non-infectious etiologies can cause fever and regional lymphadenopathy. Important infectious etiologies include streptococcal or staphylococcal lymphadenitis, cat scratch disease (<em>Bartonella </em>infection), sporotrichosis, toxoplasmosis, fungal or mycobacterial infection, <em>Spirillum minus</em> rat bite fever, anthrax, plague, syphilis, and other sexually transmitted infections [<a href="#rid1">1</a>]. Staphylococcal and streptococcal infections are more common than tularemia and often include frank cellulitis and perhaps purulence. </p><p></p><p class="bulletIndent1">As with tularemia, cat scratch disease, sporotrichosis, toxoplasmosis, <em>S. minus</em> rat bite fever, anthrax, and plague are also associated with recent exposure to the outdoors, animals, or insects; all are uncommon infections. Skin ulcers are more common with tularemia and anthrax than with cat scratch disease or plague, a necrotic ulcer with surrounding induration and edema strongly favors anthrax, and the rapid onset of tender buboes suggests plague. </p><p></p><p class="bulletIndent1">Non-infectious causes, such as malignancy or a necrotic spider bite, can also cause similar symptoms [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1">The evaluation of regional lymphadenopathy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/2871.html" rel="external">"Peripheral lymphadenopathy in children: Etiology", section on 'Localized lymphadenopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjunctival disease (oculoglandular disease)</strong> – When patients present with unilateral conjunctivitis associated with swollen lymph nodes in front of the ear on the same side (Parinaud's oculoglandular syndrome), other potential etiologies include cat scratch disease (<em>Bartonella</em> infection) and herpes simplex infection. Other more common causes of conjunctivitis include adenoviral infection and pyogenic bacterial infection. (See  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Classification and epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe pharyngitis (pharyngeal disease)</strong> – More common causes of pharyngitis are adenovirus, infectious mononucleosis, and streptococcal pharyngitis. (See  <a class="medical medical_review" href="/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults", section on 'Infectious causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonia, pulmonary infiltrates (pneumonic disease)</strong> – Clinical symptoms and radiographic findings are not sufficiently specific to distinguish tularemic pneumonia from other causes of community-acquired pneumonia. Among patients with apparent community-acquired pneumonia who have negative cultures and fail to respond to routine therapy, other diagnoses to consider include <em>Coxiella</em> infection, psittacosis, mycobacterial infection, pulmonary mycoses, and pneumonic plague [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/6992.html" rel="external">"Nonresolving pneumonia", section on 'Misdiagnosis of pathogens'</a>.) </p><p></p><p class="bulletIndent1">Pneumonic tularemia may also be mistaken for lung cancer, particularly when infectious causes are not considered and positron emission tomography (PET)/computed tomography (CT) scans are positive [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever of unknown origin (typhoidal disease</strong>) – The differential diagnosis of fever of unknown origin is broad. Other culture-negative systemic infections without localizing features include typhoid fever, brucellosis, <em>Coxiella</em> infection, tick-born relapsing fever, culture-negative endocarditis, malaria, rickettsioses, anaplasmosis, ehrlichiosis, and viral illnesses. (See  <a class="medical medical_review" href="/d/html/2737.html" rel="external">"Fever of unknown origin in adults: Etiologies"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Antimicrobial therapy (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>) should be administered promptly to all patients with suspected or confirmed tularemia. Although spontaneous resolution of infection in the absence of specific treatment has been recorded [<a href="#rid2">2</a>], early effective treatment is associated with less morbidity. Since the introduction of effective antibiotics (in particular <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a>), historical mortality rates from tularemia have decreased from as high as 60 percent in severely ill patients with pneumonic or typhoidal disease to less than 5 percent overall [<a href="#rid16">16,21,47,50</a>].</p><p class="headingAnchor" id="H3907701311"><span class="h2">Effective antibiotics</span><span class="headingEndMark"> — </span>Antimicrobials with well-established clinical efficacy include the aminoglycosides <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, the fluoroquinolones, and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>. These agents exhibit achievable minimal inhibitory concentrations (MICs) when tested using a standardized in vitro method against <em>F. tularensis</em> [<a href="#rid60">60-62</a>]. Resistance to aminoglycosides, fluoroquinolones, or tetracycline in human isolates has been uncommon [<a href="#rid63">63</a>]. However, the majority of 29 human isolates of <em>F. tularensis</em> subspecies <em>holarctica</em> in Spain were resistant to <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid63">63</a>]. In a study from France, there was no fluoroquinolone resistance among 42 <em>F. tularensis</em> subspecies <em>holarctica</em> isolates and no molecular evidence of DNA gyrase mutations (which would confer fluoroquinolone resistance) among 82 tissue samples from patients with tularemia, including those who had a suboptimal outcome with fluoroquinolone treatment [<a href="#rid64">64</a>].</p><p>Beta-lactams have been associated with clinical failure despite favorable in vitro susceptibilities [<a href="#rid65">65</a>]. Although successful use of <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> has been reported, it is not considered reliable therapy and resistant strains are prevalent in parts of Europe and Russia [<a href="#rid1">1,50,66,67</a>].</p><p class="headingAnchor" id="H816846998"><span class="h2">Regimen selection</span><span class="headingEndMark"> — </span>Our approach to regimen selection depends on the severity of infection, as below. In general, this treatment approach is based on observational data evaluating the frequency of cure and relapse with different antimicrobial agents [<a href="#rid68">68</a>]. No prospective controlled clinical trials have compared the efficacy of different drug regimens or defined the optimal duration of therapy for tularemia.</p><p class="headingAnchor" id="H2032538809"><span class="h3">Severe infection</span><span class="headingEndMark"> — </span>For patients with severe infection, we suggest <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (given intramuscularly or intravenously) or <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (given intramuscularly). Aminoglycosides are the drugs of choice for such patients, as there is the most successful clinical experience with these agents. Severe infection includes prolonged or extensive systemic symptoms prior to therapy, sepsis with or without renal failure in any form of tularemia, typhoidal tularemia, and symptomatic pneumonic tularemia. We also use an aminoglycoside when empiric treatment for tularemia is indicated in patients with an uncertain diagnosis who require hospitalization. Patients with rare complications, such as meningitis or endocarditis, are treated initially with combination therapy, ideally in consultation with an expert in infectious diseases; this is discussed separately. (See <a class="local">'Meningitis or endocarditis'</a> below.) </p><p><a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">Streptomycin</a> has traditionally been the preferred aminoglycoside because of extensive experience supporting its use, its high efficacy, and the fact that, in the United States, it is approved for the treatment of tularemia by the US Food and Drug Administration [<a href="#rid68">68</a>]. However, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> is more readily available than streptomycin. In addition, timely blood levels are usually more readily obtained for gentamicin than streptomycin, and gentamicin has less vestibular toxicity. Gentamicin is the preferred aminoglycoside for the treatment of tularemia in children for these reasons [<a href="#rid51">51</a>].</p><p>The doses are outlined in the table (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>). The duration of aminoglycoside treatment is generally 7 to 10 days; in children, the usual duration is 10 days [<a href="#rid51">51</a>]. However, the duration should be tailored to clinical signs and symptoms, including resolution of fever, and should be extended (eg, to 14 days) for especially severe cases or for patients whose response to treatment is delayed. </p><p><a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">Streptomycin</a> has been associated with high cure rates and minimal relapses. As an example, in a review of case reports and series, the cure rate among 244 patients who received streptomycin for tularemia was 97 percent, with no relapses (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>) [<a href="#rid68">68</a>]. Among the 36 patients who received <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, the cure rate was 86 percent, and there were two relapses. Subsequent case series have reported similar or higher cure rates with gentamicin [<a href="#rid8">8,69</a>]. Once-daily gentamicin dosing has been used successfully and is a more convenient option for outpatient therapy of adults [<a href="#rid19">19,70,71</a>].</p><p>Some experts have recommended that severe disease be managed with a combination of an aminoglycoside and a fluoroquinolone, although this has not been proven to be superior to an aminoglycoside alone [<a href="#rid72">72</a>]. </p><p class="headingAnchor" id="H438029240"><span class="h3">Mild or moderate infection</span></p><p class="headingAnchor" id="H438029246"><span class="h4">Adults</span><span class="headingEndMark"> — </span>Initial oral treatment is reasonable for adult patients who can be managed reliably as outpatients and for hospitalized patients without severe disease. We suggest an oral fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>) for adults with mild or moderate infection. <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is an alternative. An oral agent may also be appropriate to complete treatment in patients who responded to initial parenteral therapy. Doses are listed in the table (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>). </p><p>We prefer fluoroquinolones to a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> as oral treatment of tularemia in appropriate adults given their efficacy with lower likelihood of relapse [<a href="#rid13">13,72</a>]. The fluoroquinolones have been used successfully to treat <em>F. tularensis</em> subspecies <em>holarctica</em> infections, including in immunocompromised patients, although a higher rate of relapse was found in one small Spanish series [<a href="#rid13">13,73,74</a>]. There is less published clinical experience with using the fluoroquinolones for documented <em>F. tularensis</em> subspecies <em>tularensis</em> infections, although reports are emerging. In one series from Missouri, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, given as monotherapy or combined with inactive agents for at least 10 days, cured 9 of 10 cases of tularemia [<a href="#rid8">8</a>]. Additionally, subspecies <em>tularensis</em> is susceptible to fluoroquinolones in vitro [<a href="#rid60">60,62</a>]. Ciprofloxacin and <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> are the most active fluoroquinolones in vitro; both agents have been used successfully, although there is more published experience with ciprofloxacin. </p><p>Most published data on the use of tetracyclines in tularemia have evaluated <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>; <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> is now more commonly used because it is given only twice daily and likely has similar efficacy. In a review of case reports and series, the cure rate among 50 patients who received tetracycline was 88 percent; 12 percent relapsed [<a href="#rid68">68</a>]. Human inhalational challenge studies from the 1960s suggested that tetracycline (started early after the onset of fever) was most effective when given in a dose of 2 g daily for at least 14 days [<a href="#rid20">20</a>]. In a series that included 13 patients treated with at least 14 days doxycycline (alone or in combination with ineffective agents), 15 percent had treatment failure [<a href="#rid8">8</a>]. In contrast, a subsequent retrospective series of 16 patients treated with doxycycline monotherapy reported that all were cured with no relapses [<a href="#rid75">75</a>]. However, three of the nine patients who underwent drainage of suppurative lymph nodes prior to starting doxycycline required a repeat drainage procedure while receiving doxycycline (one patient after one week and two patients after two weeks of treatment) [<a href="#rid75">75</a>]. </p><p class="headingAnchor" id="H438029315"><span class="h4">Children</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> for treatment of children with mild or moderate infection [<a href="#rid51">51</a>]. The usual duration of gentamicin is 10 days, although in children with mild disease and no complications, it can be shortened to five to seven days if there is an adequate clinical response [<a href="#rid51">51</a>]. Oral <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> is an appropriate alternative regimen for children with mild illness who would be expected to complete the recommended 10- to 14-day course of treatment [<a href="#rid51">51</a>]; doses are listed in the table (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>).</p><p><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is not recommended for treatment of tularemia in children because it is associated with higher relapse rates and must be given for a longer course [<a href="#rid51">51</a>].</p><p>Historically, there is the most clinical experience with the aminoglycosides to treat tularemia; they are highly effective, and <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> is readily available (see <a class="local">'Severe infection'</a> above). Although tetracyclines and fluoroquinolones are effective against tularemia, relapses with the tetracyclines are more frequent, and there are less data regarding fluoroquinolone use in children, particularly for documented <em>F. tularensis</em> subspecies <em>tularensis</em> infections. </p><p>Most of the reported successful experience with the fluoroquinolones in children has been from countries other than the United States and has usually involved infections with <em>F. tularensis</em> subspecies <em>holarctica</em>. <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 7.5 mg/kg to 10 mg/kg twice daily was shown to be effective for the treatment of ulceroglandular tularemia among 12 children ages 1 to 10 years [<a href="#rid76">76</a>], and its successful use has been reported in more recent cases [<a href="#rid8">8,27</a>]. </p><p class="headingAnchor" id="H336579252"><span class="h3">Meningitis or endocarditis</span><span class="headingEndMark"> — </span>Meningitis and endocarditis are rare complications of tularemia. Both should be managed in consultation with an expert in infectious diseases. </p><p class="bulletIndent1"><span class="glyph">●</span>For adults and children with tularemic meningitis, we suggest an aminoglycoside combined with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid51">51</a>]. A combination regimen is preferred because cerebrospinal fluid levels of aminoglycosides may be erratic [<a href="#rid51">51</a>]. In general, the duration of treatment for tularemic meningitis is 14 to 21 days but should be tailored to clinical signs and symptoms, including resolution of fever. </p><p></p><p class="bulletIndent1">Studies have reported successful treatment of tularemic meningitis with <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> plus <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> as well as streptomycin plus <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> plus doxycycline, and gentamicin plus <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid41">41,77,78</a>]. However, chloramphenicol should only be used if ciprofloxacin or doxycycline cannot be given and it is available for immediate use. Chloramphenicol should not be used to treat other forms of tularemia because safer alternatives are available with greater efficacy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocarditis should also be managed initially with a combination regimen of an aminoglycoside plus a fluoroquinolone. Studies informing the optimal treatment of <em>F. tularensis</em> endocarditis are extremely limited, but case reports, including cases of prosthetic valve endocarditis, have documented favorable outcomes with two weeks of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> plus a fluoroquinolone followed by another two to four weeks of a fluoroquinolone [<a href="#rid35">35,39,40</a>]. </p><p></p><p class="headingAnchor" id="H438029423"><span class="h2">Specific circumstances</span></p><p class="headingAnchor" id="H438029443"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>The optimal therapy for tularemia in pregnant patients is undefined. Tularemia in pregnancy may lead to prematurity or fetal loss, although the extent of the risk is unknown and healthy newborns without adverse effects from maternal tularemia also have been reported [<a href="#rid15">15,79-84</a>]. <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">Gentamicin</a> and <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> have been effective in a small number of recently reported cases [<a href="#rid80">80,82</a>]. <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> was effective in a pregnant patient in Arkansas, and a prolonged course of azithromycin was effective in a patient in France where erythromycin-sensitive strains of <em>F. tularensis</em> subspecies <em>holarctica</em> predominate [<a href="#rid67">67,81</a>]. Exposure to these antibiotics early in pregnancy has been associated with an increased risk of spontaneous abortion [<a href="#rid85">85</a>]. Antibiotic use in pregnancy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Antibiotics'</a>.)</p><p class="headingAnchor" id="H438029449"><span class="h3">Immunosuppression</span><span class="headingEndMark"> — </span>Immunosuppressed patients with tularemia have an increased risk of treatment failure or relapse, and their optimal antibiotic management is unknown. We prefer an aminoglycoside for treatment of tularemia in immunocompromised patients, as used in patients with severe infection (see <a class="local">'Severe infection'</a> above). Case reports of tularemia patients with various underlying immunosuppressing conditions have documented successful treatment with <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, a fluoroquinolone, or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, alone or in combination (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>) [<a href="#rid9">9,22,25,73,86-92</a>]. Treatment may need to be prolonged beyond the usual recommended duration in patients who are slow to respond. </p><p class="headingAnchor" id="H438029467"><span class="h3">Bioterrorism event</span><span class="headingEndMark"> — </span>Treatment of tularemia from a bioterrorism event depends on the numbers of ill patients [<a href="#rid47">47</a>]. Contained attacks generally allow individual medical management, whereas resources may be more constrained in the setting of mass casualties.</p><p class="bulletIndent1"><span class="glyph">●</span>Contained casualties – Affected individuals can be managed using the same aminoglycoside or oral regimens discussed above (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>) (see <a class="local">'Severe infection'</a> above and <a class="local">'Mild or moderate infection'</a> above). In addition, the Working Group for Civilian Biodefense also includes <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> for children and <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a> for both adults and children as recommended treatment options [<a href="#rid47">47</a>]. The Working Group recommends durations of 10 days for an aminoglycoside or ciprofloxacin and 14 to 21 days for <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or chloramphenicol [<a href="#rid47">47</a>]. <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">Gentamicin</a> is preferred by the Working Group for pregnant patients, and <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or gentamicin is preferred for immunosuppressed patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mass casualties – For mass casualties, the Working Group recommends 14 days of either oral <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for most individuals [<a href="#rid47">47</a>]. Oral ciprofloxacin is preferred for pregnant patients; either <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> is preferred for immunosuppressed patients.</p><p></p><p class="headingAnchor" id="H438029461"><span class="h2">Adjunctive management</span><span class="headingEndMark"> — </span>Even with appropriate antibiotic therapy, enlarged lymph nodes can progress to fluctuance and suppuration. In such cases, incision and drainage of the lymph node are warranted. </p><p>Debridement and drainage are also warranted for empyema in the setting of pneumonic tularemia. (See  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p class="headingAnchor" id="H632674194"><span class="h2">Relapses</span><span class="headingEndMark"> — </span>Relapses can occur following any regimen but are more common when tetracyclines (bacteriostatic antimicrobials) are used for fewer than 14 days. Retreatment with the initial agent used is reasonable since resistance in clinical isolates has not been reported. If <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> was used initially, it can be used again but for a longer time (such as 21 days); alternatively, the patient can be retreated with an aminoglycoside or a fluoroquinolone. </p><p>This approach may not be effective for bioterrorism strains, however, since organisms can be engineered for resistance to commonly used agents [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H14"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H364187243"><span class="h2">Minimizing exposure</span><span class="headingEndMark"> — </span>Preventive measures include behavioral strategies to minimize the risk of exposure to the organism:</p><p class="bulletIndent1"><span class="glyph">●</span>Not using bare hands to skin or dress wild animals</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding sick or dead animals</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing masks, eye protection, and gloves when disposing of dead animals, including those brought home by cats and other pets</p><p class="bulletIndent1"><span class="glyph">●</span>Wearing clothing that covers exposed skin and that is tight at the wrists and ankles</p><p class="bulletIndent1"><span class="glyph">●</span>Using insect repellents that are also effective against ticks</p><p class="bulletIndent1"><span class="glyph">●</span>Removing ticks promptly</p><p class="bulletIndent1"><span class="glyph">●</span>Only drinking potable water</p><p class="bulletIndent1"><span class="glyph">●</span>Adequately cooking wild meats</p><p></p><p class="headingAnchor" id="H2078478525"><span class="h2">Institutional infection control</span><span class="headingEndMark"> — </span>Standard precautions are adequate for hospitalized patients with tularemia; person-to-person transmission does not occur. Whenever tularemia is suspected or proven, microbiology laboratory and autopsy personnel handling patient specimens should be notified so that they can take precautions to minimize the likelihood of exposure to <em>F. tularensis</em>. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis", section on 'Laboratory precautions'</a>.)</p><p class="headingAnchor" id="H1552267201"><span class="h2">Post-exposure prophylaxis</span><span class="headingEndMark"> — </span>The type of exposure, the length of time since the exposure, and the patient's concerns should be considered when making the decision about giving post-exposure prophylaxis. The approach also differs between adults and children. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adults</strong> – Antibiotic prophylaxis for tularemia is warranted in adults who have a suspected or proven high-risk exposure to tularemia and are identified early in the incubation period. This includes laboratory workers, autopsy personnel, and others exposed through nonintact skin, mucosal surfaces, or aerosols to materials contaminated with <em>F</em>. <em>tularensis</em>, as well as persons exposed to <em>F</em>. <em>tularensis</em> in a bioterrorism event. </p><p></p><p class="bulletIndent1">Watchful waiting without antibiotics while monitoring for fever or other symptoms of tularemia is an appropriate strategy for individuals with lower-risk exposures, those identified later in the incubation period (eg, more than a week after exposure), and in vaccinated individuals. As examples, prophylaxis is not indicated following a tick bite [<a href="#rid1">1,2</a>] or if the only risk was close contact with a patient with tularemia [<a href="#rid1">1,47</a>]. Management without antibiotics following exposure to a bioterrorism event is also recommended for persons identified after others have become symptomatic (ie, later in the incubation period) [<a href="#rid47">47</a>]. </p><p></p><p class="bulletIndent1">Additionally, individuals who have had tularemia in the past do not require antibiotic prophylaxis with subsequent exposures, other than in a bioterrorism event. Although recurrent infections have been documented (despite the understanding that recovery from tularemia results in lifelong protective immunity), most recurrences have been clinically mild ulceroglandular disease. Regimens for post-exposure prophylaxis of adults are oral <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 mg or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg, each twice daily for 14 days [<a href="#rid47">47,93</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – In general, children with exposures other than a bioterrorism event should be observed for fever or other signs of illness without prophylactic antibiotics [<a href="#rid93">93</a>]. Post-exposure prophylaxis in children is indicated following exposure to an <em>F. tularensis</em> bioweapon. The recommended doses are <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 15 mg/kg orally twice daily (not to exceed 1 gram daily) or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 2.2 mg/kg orally twice daily (for those &lt;45 kg) and 100 mg orally twice daily (for those ≥45 kg) [<a href="#rid47">47,51</a>]. Antibiotics should be given as early as possible in the incubation period following the bioweapon exposure and continued for 14 days.</p><p></p><p class="headingAnchor" id="H1994599155"><span class="h2">Investigational vaccines</span><span class="headingEndMark"> — </span>No tularemia vaccine is currently available. A vaccine prepared from the live vaccine strain (LVS) of <em>F. tularensis</em> subspecies <em>holarctica</em> that was previously used is no longer available because of concerns about its unknown mechanisms of attenuation, stability, and production. Research to develop a new vaccine is actively investigating subunit vaccines, new live strains with defined attenuation, and an improved LVS vaccine [<a href="#rid63">63,94-97</a>]. </p><p class="headingAnchor" id="H9834371"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology and transmission </strong>– Tularemia is a zoonotic infection caused by <em>Francisella tularensis</em>, an aerobic and fastidious gram-negative bacterium. Human infection occurs following contact with infected animals or invertebrate vectors. (See  <a class="medical medical_review" href="/d/html/3130.html" rel="external">"Tularemia: Microbiology, epidemiology, and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical syndromes</strong> – Tularemia usually has an abrupt onset of nonspecific symptoms, such as fever, chills, headache, and malaise following an incubation period of three to five days. Patients usually present with clinical features associated with one of six major syndromes (with occasional overlap) depending on the portal of entry: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ulceroglandular tularemia</strong> – This is the most common manifestation. Affected patients present with fever and a single erythematous papulo-ulcerative lesion with a central eschar (<a class="graphic graphic_picture graphicRef51005" href="/d/graphic/51005.html" rel="external">picture 1</a>) accompanied by tender regional lymphadenopathy. They usually report recent animal handling or exposure to potential insect vectors (particularly ticks). (See <a class="local">'Ulceroglandular disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glandular tularemia</strong> – This manifests as enlargement of a single or multiple regional lymph nodes in the absence of an identifiable skin lesion. It occurs more often in children than adults. (See <a class="local">'Glandular disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oculoglandular and pharyngeal tularemia</strong> – These are less common forms of tularemia that result from organism invasion through the conjunctivae and oral mucosa, respectively. Eye findings are usually unilateral and include pain, photophobia, and conjunctival erythema with regional adenopathy; the major features of pharyngeal tularemia are an exudative pharyngitis and tonsillitis with cervical node enlargement. (See <a class="local">'Oculoglandular disease'</a> above and <a class="local">'Pharyngeal (oropharyngeal) disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumonic tularemia</strong> – This can result from direct inhalation of <em>F. tularensis</em> (primary) or bacteremic spread to the lung (secondary). In primary disease, cough is typically nonproductive. Common findings on chest imaging include peribronchial infiltrates, lobar consolidation, pleural effusion, and hilar adenopathy. Rounded infiltrates and cavitation are uncommon. (See <a class="local">'Pneumonic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Typhoidal tularemia</strong> – This is a systemic febrile illness without prominent regional adenopathy or other clear localizing signs that does not fit another major form of the disease. The clinical presentation ranges from acute sepsis to a chronic febrile illness. (See <a class="local">'Typhoidal disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin findings </strong>– Secondary skin rashes are an underappreciated and relatively common manifestation in all forms of tularemia. These secondary eruptions are usually maculopapular, vesiculopapular, erythema multiforme, erythema nodosum, or urticarial; some have been mistaken for varicella or drug eruptions. (See <a class="local">'Secondary skin manifestations'</a> above and <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect tularemia</strong> – Tularemia should be suspected in patients with features compatible with one of these clinical syndromes and epidemiologic risk factors. A history of animal (particularly wild animal) exposure or insect bites should heighten suspicion for tularemia; the patient's location (<a class="graphic graphic_figure graphicRef68457" href="/d/graphic/68457.html" rel="external">figure 1</a>), activities, and travel history should also inform the likelihood of tularemia. Because laboratory confirmation may be delayed, the initial diagnosis is often made presumptively. Clusters of cases, particularly of infections consistent with pneumonic tularemia in the absence of typical exposures, should raise suspicion for the possibility of a bioterrorism event. (See <a class="local">'Clinical suspicion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – When tularemia is clinically suspected, serology for <em>F. tularensis</em> should be submitted at the time of presentation and again at least two to four weeks later. A single tube agglutination titer of 1:160 or higher or a single microagglutination titer of 1:128 or higher is supportive of the diagnosis; a fourfold or greater change in titer between acute and convalescent serum specimens is confirmatory. Specimens should also be sent for culture with specific instructions to the laboratory that tularemia is suspected; cultures are diagnostic if positive but do not rule out the possibility of tularemia if negative. (See <a class="local">'Microbiologic diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Antibiotics are the cornerstone of therapy and should be administered promptly to patients with documented or suspected tularemia. Adjunctive management includes incision and drainage of suppurated lymph nodes. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe infection </strong>– For adults and children with severe infection, we suggest <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Streptomycin has traditionally been the preferred aminoglycoside because of greater experience with this agent, but gentamicin is also effective, is more readily available, and has less associated vestibular toxicity. (See <a class="local">'Severe infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild infection</strong> – For adults with mild or moderate infection, we suggest an oral fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is an acceptable alternative oral agent. For children with mild or moderate infection, we suggest <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). An oral fluoroquinolone is an acceptable alternative for children with mild disease. (See <a class="local">'Mild or moderate infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Doses and durations</strong> – These are listed in the table (<a class="graphic graphic_table graphicRef77460" href="/d/graphic/77460.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Preventive measure include behavioral strategies to minimize the risk of exposure (eg, avoiding sick or dead animals, not using bare hands to skin game, tick or insect bite prevention). We suggest antibiotic prophylaxis for adults with nonintact skin, mucosal surface, or inhalational exposure to materials contaminated with <em>F. tularensis</em> and for individuals exposed to <em>F. tularensis</em> in a bioterrorism event (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Either oral <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> can be used for post-exposure prophylaxis. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Auwaerter PG, Penn RL. Francisella tularensis (Tularemia). In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed, Bennet JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2020. p.2759.</li><li><a class="nounderline abstract_t">Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 1985; 64:251.</a></li><li><a class="nounderline abstract_t">Eliasson H, Bäck E. Tularaemia in an emergent area in Sweden: an analysis of 234 cases in five years. Scand J Infect Dis 2007; 39:880.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Tularemia - Missouri, 2000-2007. MMWR Morb Mortal Wkly Rep 2009; 58:744.</a></li><li><a class="nounderline abstract_t">Pedati C, House J, Hancock-Allen J, et al. Notes from the Field: Increase in Human Cases of Tularemia--Colorado, Nebraska, South Dakota, and Wyoming, January-September 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1317.</a></li><li><a class="nounderline abstract_t">Darmon-Curti A, Darmon F, Edouard S, et al. Tularemia: A Case Series of Patients Diagnosed at the National Reference Center for Rickettsioses From 2008 to 2017. Open Forum Infect Dis 2020; 7:ofaa440.</a></li><li><a class="nounderline abstract_t">Smego RA Jr, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore) 1999; 78:38.</a></li><li><a class="nounderline abstract_t">Weber IB, Turabelidze G, Patrick S, et al. Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases. Clin Infect Dis 2012; 55:1283.</a></li><li><a class="nounderline abstract_t">Calin R, Caumes E, Reibel F, et al. Severe glandular tularemia in a patient treated with anti-tumour necrosis factor for psoriatic arthritis. Int J Infect Dis 2017; 60:1.</a></li><li><a class="nounderline abstract_t">Eren Gok S, Kocagul Celikbas A, Baykam N, et al. Evaluation of tularemia cases focusing on the oculoglandular form. J Infect Dev Ctries 2014; 8:1277.</a></li><li><a class="nounderline abstract_t">Raja H, Starr MR, Bakri SJ. Ocular manifestations of tick-borne diseases. Surv Ophthalmol 2016; 61:726.</a></li><li><a class="nounderline abstract_t">Terrada C, Azza S, Bodaghi B, et al. Rabbit hunter uveitis: case report of tularemia uveitis. BMC Ophthalmol 2016; 16:157.</a></li><li><a class="nounderline abstract_t">Meric M, Willke A, Finke EJ, et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS 2008; 116:66.</a></li><li><a class="nounderline abstract_t">Ulu-Kilic A, Gulen G, Sezen F, et al. Tularemia in central Anatolia. Infection 2013; 41:391.</a></li><li><a class="nounderline abstract_t">DIENST FT Jr. Tularemia: a perusal of three hundred thirty-nine cases. J La State Med Soc 1963; 115:114.</a></li><li><a class="nounderline abstract_t">Thomas LD, Schaffner W. Tularemia pneumonia. Infect Dis Clin North Am 2010; 24:43.</a></li><li><a class="nounderline abstract_t">Väyrynen SA, Saarela E, Henry J, et al. Pneumonic tularaemia: experience of 58 cases from 2000 to 2012 in Northern Finland. Infect Dis (Lond) 2017; 49:758.</a></li><li><a class="nounderline abstract_t">Su TY, Shie SS, Chia JH, Huang CT. Case Report of Low Virulence Francisella tularensis Presented as Severe Bacteremic Pneumonia. Medicine (Baltimore) 2016; 95:e3390.</a></li><li><a class="nounderline abstract_t">Matyas BT, Nieder HS, Telford SR 3rd. Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann N Y Acad Sci 2007; 1105:351.</a></li><li><a class="nounderline abstract_t">Williams MS, Baker MR, Guina T, et al. Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy. Front Med (Lausanne) 2019; 6:229.</a></li><li><a class="nounderline abstract_t">Scofield RH, Lopez EJ, McNabb SJ. Tularemia pneumonia in Oklahoma, 1982-1987. J Okla State Med Assoc 1992; 85:165.</a></li><li><a class="nounderline abstract_t">Alias T, Fallahzadeh MK, Berhe M. Tularemia presenting as pulmonary nodules in an immunocompromised patient. Proc (Bayl Univ Med Cent) 2017; 30:175.</a></li><li><a class="nounderline abstract_t">Pettersson T, Nyberg P, Nordström D, Riska H. Similar pleural fluid findings in pleuropulmonary tularemia and tuberculous pleurisy. Chest 1996; 109:572.</a></li><li><a class="nounderline abstract_t">Lester Rothfeldt LK, Jacobs RF, Wheeler JG, et al. Variation in Tularemia Clinical Manifestations-Arkansas, 2009-2013. Open Forum Infect Dis 2017; 4:ofx027.</a></li><li><a class="nounderline abstract_t">Bahuaud O, Le Brun C, Lemaignen A. Host Immunity and Francisella tularensis: A Review of Tularemia in Immunocompromised Patients. Microorganisms 2021; 9.</a></li><li><a class="nounderline abstract_t">Syrjälä H, Karvonen J, Salminen A. Skin manifestations of tularemia: a study of 88 cases in northern Finland during 16 years (1967-1983). Acta Derm Venereol 1984; 64:513.</a></li><li><a class="nounderline abstract_t">Jounio U, Renko M, Uhari M. An outbreak of holarctica-type tularemia in pediatric patients. Pediatr Infect Dis J 2010; 29:160.</a></li><li><a class="nounderline abstract_t">Polat M, Karapınar T, Sırmatel F. Dermatological aspects of tularaemia: a study of 168 cases. Clin Exp Dermatol 2018; 43:770.</a></li><li><a class="nounderline abstract_t">Marquart JD, Clifford R. Pneumonic tularemia presenting with a vesicular eruption. Cutis 2015; 95:E17.</a></li><li><a class="nounderline abstract_t">Şenel E, Satılmış Ö, Acar B. Dermatologic manifestations of tularemia: a study of 151 cases in the mid-Anatolian region of Turkey. Int J Dermatol 2015; 54:e33.</a></li><li><a class="nounderline abstract_t">Chitadze N, Kuchuloria T, Clark DV, et al. Water-borne outbreak of oropharyngeal and glandular tularemia in Georgia: investigation and follow-up. Infection 2009; 37:514.</a></li><li><a class="nounderline abstract_t">Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. Arch Intern Med 1987; 147:265.</a></li><li><a class="nounderline abstract_t">Briere M, Kaladji A, Douane F, et al. Francisella tularensis aortitis. Infection 2016; 44:263.</a></li><li><a class="nounderline abstract_t">Rawal H, Patel A, Moran M. Unusual case of prosthetic joint infection caused by Francisella Tularensis. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Gaci R, Alauzet C, Selton-Suty C, et al. Francisella tularensis endocarditis: two case reports and a literature review. Infect Dis (Lond) 2017; 49:128.</a></li><li><a class="nounderline abstract_t">Frischknecht M, Meier A, Mani B, et al. Tularemia: an experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature. Infection 2019; 47:683.</a></li><li><a class="nounderline abstract_t">Kocabaş E, Özgür Gündeşlioğlu Ö, Kılıç Çil M, et al. A rare cause of granulomatous hepatitis: Tularemia. J Infect Public Health 2020; 13:1003.</a></li><li><a class="nounderline abstract_t">Fohle E, Smith BA, Guerrero DM. A Rare Case of Spontaneous Splenic Rupture Secondary to Tularemia Following a Cat Bite. Cureus 2021; 13:e13218.</a></li><li><a class="nounderline abstract_t">Olivo CA, Dysart C, Haque J, et al. A Rare Cause of Prosthetic Valve Infective Endocarditis: Francisella tularensis holarctica. WMJ 2019; 118:196.</a></li><li><a class="nounderline abstract_t">Kaeppler M, Kapoor R, Shah N, et al. Tick-Borne Illness and Infective Endocarditis: A Rare Case of Tularemia. CASE (Phila) 2020; 4:78.</a></li><li><a class="nounderline abstract_t">Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol 2009; 66:523.</a></li><li><a class="nounderline abstract_t">Ducatez N, Melboucy S, Bentayeb H, et al. A case of Francisella tularensis meningitis in a 64-year-old man treated with quinolones. Infect Dis Now 2022; 52:107.</a></li><li><a class="nounderline abstract_t">Venkatesan S, Johnston C, Mehrizi MZ. A rare case of tularemic meningitis in the United States from aerosolized Francisella tularensis. J Am Coll Emerg Physicians Open 2020; 1:238.</a></li><li><a class="nounderline abstract_t">Ylipalosaari P, Ala-Kokko TI, Tuominen H, Syrjälä H. Guillain-Barré syndrome and ulceroglandular tularemia. Infection 2013; 41:881.</a></li><li><a class="nounderline abstract_t">Blech B, Christiansen M, Asbury K, et al. Polyneuritis cranialis after acute tularemia infection: A case study. Muscle Nerve 2020; 61:E1.</a></li><li><a class="nounderline abstract_t">Landais C, Levy PY, Habib G, Raoult D. Pericardial effusion as the only manifestation of infection with Francisella tularensis: a case report. J Med Case Rep 2008; 2:206.</a></li><li><a class="nounderline abstract_t">Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Bioterrorism Readiness Plan: A Template for Healthcare Facilities. https://emergency.cdc.gov/bioterrorism/pdf/13apr99APIC-CDCBioterrorism.pdf (Accessed on May 20, 2022).</li><li class="breakAll">Dietrich EA, Peterson JM. Francisella. In: Manual of Clinical Microbiology, 12th ed, Jorgensen J, Pfaller M, Carroll K, et al (Eds), American Society for Microbiology Press, Washington DC 2019. p.871.</li><li><a class="nounderline abstract_t">Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci 2007; 1105:378.</a></li><li class="breakAll">American Academy of Pediatrics. Tularemia. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.822.</li><li><a class="nounderline abstract_t">Nakajima R, Escudero R, Molina DM, et al. Towards Development of Improved Serodiagnostics for Tularemia by Use of Francisella tularensis Proteome Microarrays. J Clin Microbiol 2016; 54:1755.</a></li><li><a class="nounderline abstract_t">Maurin M. Francisella tularensis, Tularemia and Serological Diagnosis. Front Cell Infect Microbiol 2020; 10:512090.</a></li><li><a class="nounderline abstract_t">Molins CR, Carlson JK, Coombs J, Petersen JM. Identification of Francisella tularensis subsp. tularensis A1 and A2 infections by real-time polymerase chain reaction. Diagn Microbiol Infect Dis 2009; 64:6.</a></li><li><a class="nounderline abstract_t">Larson MA, Sayood K, Bartling AM, et al. Differentiation of Francisella tularensis Subspecies and Subtypes. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Banada PP, Deshpande S, Chakravorty S, et al. Sensitive Detection of Francisella tularensis Directly from Whole Blood by Use of the GeneXpert System. J Clin Microbiol 2017; 55:291.</a></li><li><a class="nounderline abstract_t">Roth S, Thurner L, Becker SL. Application of the FilmArray® BioThreat Panel for molecular diagnosis of human tularemia. Ticks Tick Borne Dis 2021; 12:101792.</a></li><li><a class="nounderline abstract_t">Sateia HF, Melia MT, Cofrancesco J Jr. Tularemia presenting as suspected necrotic arachnidism. Clin Case Rep 2017; 5:497.</a></li><li><a class="nounderline abstract_t">Martinet P, Khatchatourian L, Saidani N, et al. Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia? Infect Dis Now 2021; 51:607.</a></li><li><a class="nounderline abstract_t">Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008; 52:2276.</a></li><li><a class="nounderline abstract_t">Georgi E, Schacht E, Scholz HC, Splettstoesser WD. Standardized broth microdilution antimicrobial susceptibility testing of Francisella tularensis subsp. holarctica strains from Europe and rare Francisella species. J Antimicrob Chemother 2012; 67:2429.</a></li><li><a class="nounderline abstract_t">Heine HS, Miller L, Halasohoris S, Purcell BK. In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Conlan JW, Sjöstedt A, Gelhaus HC, et al. Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 ΔclpB, to Prevent Tularemia. Pathogens 2021; 10.</a></li><li><a class="nounderline abstract_t">Sutera V, Hoarau G, Renesto P, et al. In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure. Int J Antimicrob Agents 2017; 50:377.</a></li><li><a class="nounderline abstract_t">Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis 1993; 17:976.</a></li><li><a class="nounderline abstract_t">Origgi FC, Frey J, Pilo P. Characterisation of a new group of Francisella tularensis subsp. holarctica in Switzerland with altered antimicrobial susceptibilities, 1996 to 2013. Euro Surveill 2014; 19.</a></li><li><a class="nounderline abstract_t">Johnsrud JJ, Smith CR, Bradsher RW. Serendipitous Treatment of Tularemia in Pregnancy. Open Forum Infect Dis 2019; 6:ofz413.</a></li><li><a class="nounderline abstract_t">Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19:42.</a></li><li><a class="nounderline abstract_t">Snowden J, Stovall S. Tularemia: retrospective review of 10 years' experience in Arkansas. Clin Pediatr (Phila) 2011; 50:64.</a></li><li><a class="nounderline abstract_t">Hassoun A, Spera R, Dunkel J. Tularemia and once-daily gentamicin. Antimicrob Agents Chemother 2006; 50:824.</a></li><li><a class="nounderline abstract_t">Dietrich T, Garcia K, Strain J, Ashurst J. Extended-Interval Gentamicin Dosing for Pulmonic Tularemia. Case Rep Infect Dis 2019; 2019:9870510.</a></li><li><a class="nounderline abstract_t">Eliasson H, Broman T, Forsman M, Bäck E. Tularemia: current epidemiology and disease management. Infect Dis Clin North Am 2006; 20:289.</a></li><li><a class="nounderline abstract_t">Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 1999; 29:922.</a></li><li><a class="nounderline abstract_t">Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with ciprofloxacin. Clin Infect Dis 2000; 31:623.</a></li><li><a class="nounderline abstract_t">Rojas-Moreno C, Bhartee H, Vasudevan A, et al. Tetracyclines for Treatment of Tularemia: A Case Series. Open Forum Infect Dis 2018; 5:ofy176.</a></li><li><a class="nounderline abstract_t">Johansson A, Berglund L, Gothefors L, et al. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19:449.</a></li><li><a class="nounderline abstract_t">Barbaz M, Piau C, Tadie JM, et al. Rhombencephalitis caused by Francisella tularensis. J Clin Microbiol 2013; 51:3454.</a></li><li><a class="nounderline abstract_t">Page J, Wittler RR. An 8-year-old boy with Fever, axillary ulcerative lesion, and altered mental status. Clin Infect Dis 2009; 48:1266.</a></li><li><a class="nounderline abstract_t">Pullen RL, Stuart BM. Tularemia: Analysis of 22 cases. JAMA 1945; 129:495.</a></li><li><a class="nounderline abstract_t">Yeşilyurt M, Kiliç S, Çelebі B, Gül S. Tularemia during pregnancy: report of four cases. Scand J Infect Dis 2013; 45:324.</a></li><li><a class="nounderline abstract_t">Dentan C, Pavese P, Pelloux I, et al. Treatment of tularemia in pregnant woman, France. Emerg Infect Dis 2013; 19:996.</a></li><li><a class="nounderline abstract_t">Yilmaz GR, Guven T, Guner R, et al. Tularemia during pregnancy: three cases. Vector Borne Zoonotic Dis 2014; 14:171.</a></li><li><a class="nounderline abstract_t">Ata N, Kılıç S, Övet G, et al. Tularemia during pregnancy. Infection 2013; 41:753.</a></li><li><a class="nounderline abstract_t">Celik T, Kosker M, Kirboga K. An atypical case of tularemia presented with pseudoptosis. Infection 2014; 42:785.</a></li><li><a class="nounderline abstract_t">Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ 2017; 189:E625.</a></li><li><a class="nounderline abstract_t">Khoury JA, Bohl DL, Hersh MJ, et al. Tularemia in a kidney transplant recipient: an unsuspected case and literature review. Am J Kidney Dis 2005; 45:926.</a></li><li><a class="nounderline abstract_t">Naughton M, Brown R, Adkins D, DiPersio J. Tularemia--an unusual cause of a solitary pulmonary nodule in the post-transplant setting. Bone Marrow Transplant 1999; 24:197.</a></li><li><a class="nounderline abstract_t">Ozkok A, Karadenizli A, Odabas AR. Tularemia in a kidney transplant recipient. Am J Kidney Dis 2012; 60:679.</a></li><li><a class="nounderline abstract_t">Weile J, Seibold E, Knabbe C, et al. Treatment of tularemia in patient with chronic graft-versus-host disease. Emerg Infect Dis 2013; 19:771.</a></li><li><a class="nounderline abstract_t">James J, Kaul DR, Goldberger ZD, et al. CLINICAL PROBLEM-SOLVING. Back to Nature. N Engl J Med 2015; 373:2271.</a></li><li><a class="nounderline abstract_t">Bahuaud O, Le Brun C, Chalopin T, et al. Severe infections due to Francisella tularensis ssp. holarctica in solid organ transplant recipient: report of two cases and review of literature. BMC Infect Dis 2019; 19:238.</a></li><li><a class="nounderline abstract_t">Nelson CA, Murua C, Jones JM, et al. Francisella tularensis Transmission by Solid Organ Transplantation, 20171. Emerg Infect Dis 2019; 25:767.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Outbreak of tularemia among commercially distributed prairie dogs, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:688, 699.</a></li><li><a class="nounderline abstract_t">Elkins KL, Kurtz SL, De Pascalis R. Progress, challenges, and opportunities in Francisella vaccine development. Expert Rev Vaccines 2016; 15:1183.</a></li><li><a class="nounderline abstract_t">Mulligan MJ, Stapleton JT, Keitel WA, et al. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine 2017; 35:4730.</a></li><li><a class="nounderline abstract_t">Putzova D, Senitkova I, Stulik J. Tularemia vaccines. Folia Microbiol (Praha) 2016; 61:495.</a></li><li><a class="nounderline abstract_t">Sunagar R, Kumar S, Franz BJ, Gosselin EJ. Tularemia vaccine development: paralysis or progress? Vaccine (Auckl) 2016; 6:9.</a></li></ol></div><div id="topicVersionRevision">Topic 3141 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Auwaerter PG, Penn RL. Francisella tularensis (Tularemia). In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed, Bennet JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2020. p.2759.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3892222" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tularemia: a 30-year experience with 88 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17886125" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tularaemia in an emergent area in Sweden: an analysis of 234 cases in five years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609248" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tularemia - Missouri, 2000-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632662" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Notes from the Field: Increase in Human Cases of Tularemia--Colorado, Nebraska, South Dakota, and Wyoming, January-September 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33209946" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tularemia: A Case Series of Patients Diagnosed at the National Reference Center for Rickettsioses From 2008 to 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990353" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lymphocutaneous syndrome. A review of non-sporothrix causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911645" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical recognition and management of tularemia in Missouri: a retrospective records review of 121 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28450199" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Severe glandular tularemia in a patient treated with anti-tumour necrosis factor for psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313604" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation of tularemia cases focusing on the oculoglandular form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060746" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ocular manifestations of tick-borne diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27585457" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rabbit hunter uveitis: case report of tularemia uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254782" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104256" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tularemia in central Anatolia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14027775" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tularemia: a perusal of three hundred thirty-nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171544" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tularemia pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28618894" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pneumonic tularaemia: experience of 58 cases from 2000 to 2012 in Northern Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175638" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Case Report of Low Virulence Francisella tularensis Presented as Severe Bacteremic Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442781" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31696118" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593309" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tularemia pneumonia in Oklahoma, 1982-1987.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28405072" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tularemia presenting as pulmonary nodules in an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8620743" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Similar pleural fluid findings in pleuropulmonary tularemia and tuberculous pleurisy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480295" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Variation in Tularemia Clinical Manifestations-Arkansas, 2009-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34946140" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Host Immunity and Francisella tularensis: A Review of Tularemia in Immunocompromised Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6084923" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Skin manifestations of tularemia: a study of 88 cases in northern Finland during 16 years (1967-1983).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918211" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : An outbreak of holarctica-type tularemia in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29761532" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dermatological aspects of tularaemia: a study of 168 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25942033" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumonic tularemia presenting with a vesicular eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208535" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dermatologic manifestations of tularemia: a study of 151 cases in the mid-Anatolian region of Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826763" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Water-borne outbreak of oropharyngeal and glandular tularemia in Georgia: investigation and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3813743" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factors associated with a poor outcome in tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26189939" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Francisella tularensis aortitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025776" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Unusual case of prosthetic joint infection caused by Francisella Tularensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27564142" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Francisella tularensis endocarditis: two case reports and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30656604" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tularemia: an experience of 13 cases including a rare myocarditis in a referral center in Eastern Switzerland (Central Europe) and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31937491" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A rare cause of granulomatous hepatitis: Tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33717752" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Rare Case of Spontaneous Splenic Rupture Secondary to Tularemia Following a Cat Bite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31978290" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Rare Cause of Prosthetic Valve Infective Endocarditis: Francisella tularensis holarctica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32337395" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tick-Borne Illness and Infective Endocarditis: A Rare Case of Tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364939" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tularemic meningitis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34242839" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A case of Francisella tularensis meningitis in a 64-year-old man treated with quinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33000038" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A rare case of tularemic meningitis in the United States from aerosolized Francisella tularensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23712689" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Guillain-Barrésyndrome and ulceroglandular tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31587301" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Polyneuritis cranialis after acute tularemia infection: A case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18554395" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pericardial effusion as the only manifestation of infection with Francisella tularensis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386933" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tularemia as a biological weapon: medical and public health management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386933" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tularemia as a biological weapon: medical and public health management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386933" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tularemia as a biological weapon: medical and public health management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468229" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : New approaches to diagnosis and therapy of tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468229" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New approaches to diagnosis and therapy of tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27098957" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Towards Development of Improved Serodiagnostics for Tularemia by Use of Francisella tularensis Proteome Microarrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33194778" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Francisella tularensis, Tularemia and Serological Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19232853" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Identification of Francisella tularensis subsp. tularensis A1 and A2 infections by real-time polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31941692" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Differentiation of Francisella tularensis Subspecies and Subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27847371" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sensitive Detection of Francisella tularensis Directly from Whole Blood by Use of the GeneXpert System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34330678" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Application of the FilmArray®BioThreat Panel for molecular diagnosis of human tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396776" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tularemia presenting as suspected necrotic arachnidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34242840" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411318" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763567" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Standardized broth microdilution antimicrobial susceptibility testing of Francisella tularensis subsp. holarctica strains from Europe and rare Francisella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674048" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34201577" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4ΔclpB, to Prevent Tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28689870" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8110955" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tularemia: treatment failures with outpatient use of ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25080140" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Characterisation of a new group of Francisella tularensis subsp. holarctica in Switzerland with altered antimicrobial susceptibilities, 1996 to 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31660371" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Serendipitous Treatment of Tularemia in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948556" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Streptomycin and alternative agents for the treatment of tularemia: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837613" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Tularemia: retrospective review of 10 years' experience in Arkansas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436758" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tularemia and once-daily gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662926" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Extended-Interval Gentamicin Dosing for Pulmonic Tularemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16762740" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tularemia: current epidemiology and disease management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589911" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of tularemia with fluoroquinolones: two cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987739" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of tularemia with ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191155" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tetracyclines for Treatment of Tularemia: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819342" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ciprofloxacin for treatment of tularemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23903544" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rhombencephalitis caused by Francisella tularensis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344255" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : An 8-year-old boy with Fever, axillary ulcerative lesion, and altered mental status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Tularemia: Analysis of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22998506" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Tularemia during pregnancy: report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735285" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treatment of tularemia in pregnant woman, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359416" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tularemia during pregnancy: three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23559358" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tularemia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24659144" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : An atypical case of tularemia presented with pseudoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461374" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Use of antibiotics during pregnancy and risk of spontaneous abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15861359" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tularemia in a kidney transplant recipient: an unsuspected case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10455349" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Tularemia--an unusual cause of a solitary pulmonary nodule in the post-transplant setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901596" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Tularemia in a kidney transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23647853" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of tularemia in patient with chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630146" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : CLINICAL PROBLEM-SOLVING. Back to Nature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30849949" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Severe infections due to Francisella tularensis ssp. holarctica in solid organ transplant recipient: report of two cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730826" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Francisella tularensis Transmission by Solid Organ Transplantation, 20171.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233912" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Outbreak of tularemia among commercially distributed prairie dogs, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27010448" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Progress, challenges, and opportunities in Francisella vaccine development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750854" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194547" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Tularemia vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27200274" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Tularemia vaccine development: paralysis or progress?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
